These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19825951)

  • 21. A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody.
    Farrugia W; Scott AM; Ramsland PA
    PLoS One; 2009 Nov; 4(11):e7777. PubMed ID: 19901987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-in-Humans Imaging with
    Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD
    J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
    Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
    Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
    Wong JY; Raubitschek A; Yamauchi D; Williams LE; Wu AM; Yazaki P; Shively JE; Colcher D; Somlo G
    Cancer Biother Radiopharm; 2010 Aug; 25(4):387-94. PubMed ID: 20707718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers.
    Hu Z; Gao J; Zhang D; Liu Q; Yan L; Gao L; Liu J; Liu D; Zhang S; Lin B
    PLoS One; 2013; 8(2):e57250. PubMed ID: 23468946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
    Galsky MD; Eisenberger M; Moore-Cooper S; Kelly WK; Slovin SF; DeLaCruz A; Lee Y; Webb IJ; Scher HI
    J Clin Oncol; 2008 May; 26(13):2147-54. PubMed ID: 18362364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
    Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
    Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    Scott AM; Lee FT; Hopkins W; Cebon JS; Wheatley JM; Liu Z; Smyth FE; Murone C; Sturrock S; MacGregor D; Hanai N; Inoue K; Yamasaki M; Brechbiel MW; Davis ID; Murphy R; Hannah A; Lim-Joon M; Chan T; Chong G; Ritter G; Hoffman EW; Burgess AW; Old LJ
    J Clin Oncol; 2001 Oct; 19(19):3976-87. PubMed ID: 11579119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
    Baselga J; Pfister D; Cooper MR; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
    J Clin Oncol; 2000 Feb; 18(4):904-14. PubMed ID: 10673534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
    Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
    Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 1 and Biodistribution Study of ABT-806i, an
    Gan HK; Burge M; Solomon B; Lee ST; Holen KD; Zhang Y; Ciprotti M; Lee FT; Munasinghe W; Fischer J; Ansell P; Fox G; Xiong H; Reilly EB; Humerickhouse R; Scott AM
    J Nucl Med; 2021 Jun; 62(6):787-794. PubMed ID: 33509972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
    Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
    Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
    Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
    Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
    Gan HK; Parakh S; Lee FT; Tebbutt NC; Ameratunga M; Lee ST; O'Keefe GJ; Gong SJ; Vanrenen C; Caine J; Giovannetti M; Murone C; Scott FE; Guo N; Burvenich IJG; Paine C; Macri MJ; Kotsuma M; Senaldi G; Venhaus R; Scott AM
    Invest New Drugs; 2022 Aug; 40(4):747-755. PubMed ID: 35404015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
    Smith-Jones PM; Pandit-Taskar N; Cao W; O'Donoghue J; Philips MD; Carrasquillo J; Konner JA; Old LJ; Larson SM
    Nucl Med Biol; 2008 Apr; 35(3):343-51. PubMed ID: 18355690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
    Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
    Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
    Smaletz O; Ismael G; Del Pilar Estevez-Diz M; Nascimento ILO; de Morais ALG; Cunha-Junior GF; Azevedo SJ; Alves VA; Moro AM; Yeda FP; Dos Santos ML; Majumder I; Hoffman EW
    Int J Gynecol Cancer; 2021 Apr; 31(4):562-568. PubMed ID: 33664128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.